NRX Pharmaceuticals Q1 EPS $(0.74) Misses $(0.37) Estimate
Portfolio Pulse from Benzinga Newsdesk
NRX Pharmaceuticals (NRXP) reported a Q1 EPS loss of $(0.74), missing the consensus estimate of $(0.37) by 100%. This represents a 53.75% improvement over the $(1.60) per share loss from the same period last year.
May 14, 2024 | 8:37 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
NRX Pharmaceuticals reported a larger than expected Q1 loss per share of $(0.74), which was a significant miss compared to the $(0.37) estimate but showed improvement from last year's $(1.60) loss.
The reported earnings miss is likely to negatively impact investor sentiment in the short term, as the loss was significantly larger than expected. However, the improvement from the previous year's loss may provide some mitigating context.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100